| Budget Amount *help |
¥17,520,000 (Direct Cost: ¥15,300,000、Indirect Cost: ¥2,220,000)
Fiscal Year 2007: ¥9,620,000 (Direct Cost: ¥7,400,000、Indirect Cost: ¥2,220,000)
Fiscal Year 2006: ¥7,900,000 (Direct Cost: ¥7,900,000)
|
|---|
| Research Abstract |
In this study, we examined the pathophysiological roles of PGE_2 synthase (mPGES-1), a terminal PGE_2-biosynthetic enzyme in the arachidonic acid metabolism, using mPGES-1 knockout mice.
1. mPGES-1 and cancer : Luwis lung carcinoma (LLC) cells stably overexpressing mPGES-1 proliferated more rapidly in vitro and, when implanted into C57BL/6 mice, formed larger and more subcutaneous tumors and lung metastatic foci than did parental cells. Conversely, mPGES-knockdown LLC cells produced smaller and fewer tumors in implanted mice mPGES-1-null mice implanted with LLC cells showed resistance to tumor growth and metastasis associated with reduced angiogenesis compared with replicate wild-type mice Moreover, azoxymethanie-induced colon carcinogenesis was markedly reduced in mPGES-1-null mice relative to that in wild-type mice These results indicate that mPGES-1 expressed in tumor cells as well as in host tissues participates in tumorigenesis.
2. mPGES-1 and inflammation : In carageenan- and thioglycolate-induced peritonitis models, leukocyte infiltration was markedly mitigated in mPGES-1-deficient mice as compared with that m control mice.
3. mPGES-1 and bone : mPGES-1 deficiency was associated with impaired fracture healing, but not with bone loss or osteoarthritis, in mouse models of skeletal disorders.
4. mPGES-1 and colitis : Dextran sulfate-induced colitis (a model of inflammatory bowel disease), as evaluated by intestinal histology, bleeding and cytokine expression, was significantly exacerbated in mPGES-1 knockout mice compared with control mice.
Thus, novel drugs that could inhibit mPGES-1 would be useful for treatments of cancer and inflammation, yet they might have some adverse effects on bone and gastrointestinal tract.
|
